Darwin Lewis Acquires 3,955 Shares of Lifevantage (NASDAQ:LFVN) Stock

Lifevantage Corporation (NASDAQ:LFVN) Director Darwin Lewis acquired 3,955 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was purchased at an average price of $5.22 per share, for a total transaction of $20,645.10. Following the completion of the transaction, the director directly owned 135,508 shares in the company, valued at approximately $707,351.76. The trade was a 3.01% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Darwin Lewis also recently made the following trade(s):

• On Monday, December 15th, Darwin Lewis bought 805 shares of Lifevantage stock. The shares were purchased at an average price of $6.54 per share, with a total value of $5,264.70.

Lifevantage Trading Up 3.2%

Shares of LFVN traded up $0.16 during trading hours on Wednesday, hitting $5.09. 356,709 shares of the stock traded hands, compared to its average volume of 281,196. The business has a fifty day moving average of $6.08 and a 200-day moving average of $8.69. The firm has a market capitalization of $65.12 million, a PE ratio of 8.48 and a beta of 0.33. Lifevantage Corporation has a 1-year low of $3.90 and a 1-year high of $19.41.

Lifevantage (NASDAQ:LFVN) last released its earnings results on Wednesday, February 4th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.07). Lifevantage had a net margin of 3.74% and a return on equity of 29.59%. The business had revenue of $48.93 million for the quarter, compared to analyst estimates of $54.40 million. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS.

Lifevantage Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.045 per share. The ex-dividend date is Monday, March 2nd. This represents a $0.18 dividend on an annualized basis and a yield of 3.5%. Lifevantage’s dividend payout ratio (DPR) is 30.00%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LFVN. Weiss Ratings reissued a “hold (c)” rating on shares of Lifevantage in a research note on Monday, December 29th. Wall Street Zen cut shares of Lifevantage from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Loop Capital set a $5.00 price objective on shares of Lifevantage in a research report on Thursday, February 5th. Finally, Lake Street Capital reiterated a “buy” rating on shares of Lifevantage in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $5.00.

Institutional Investors Weigh In On Lifevantage

Several hedge funds have recently bought and sold shares of the company. Police & Firemen s Retirement System of New Jersey acquired a new stake in Lifevantage during the 2nd quarter valued at $31,000. JPMorgan Chase & Co. lifted its stake in shares of Lifevantage by 870.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after buying an additional 4,499 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Lifevantage during the 4th quarter worth about $74,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Lifevantage in the 2nd quarter valued at about $76,000. Finally, BNP Paribas Financial Markets raised its holdings in Lifevantage by 2,555.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock valued at $80,000 after acquiring an additional 5,904 shares during the period. 35.32% of the stock is currently owned by institutional investors and hedge funds.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.